EpiVax says Novozymes Collaboration has $3bn Potential
by: Gareth Macdonald
EpiVax says combining its immune ‘off switch’ drugs with Novozymes’ half-life boosting Albufuse platform could deliver a $3bn (€2.2bn) section of the autoimmune disease market.
Full Article in in-Pharma Technologist.com – https://bit.ly/EpiVaxNZinterPR